Improvement in Brachial Endothelial Vasomotor Function and Brachial-Ankle Pulse Wave Velocity Reduces the Residual Risk for Cardiovascular Events after Optimal Medical Treatment in Patients with Coronary Artery Disease.
Arterial stiffness
Endothelial function
Flow-mediated dilation
Pulse wave velocity
Residual risk
Journal
Journal of atherosclerosis and thrombosis
ISSN: 1880-3873
Titre abrégé: J Atheroscler Thromb
Pays: Japan
ID NLM: 9506298
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
pubmed:
25
11
2020
medline:
5
2
2022
entrez:
24
11
2020
Statut:
ppublish
Résumé
To examine whether improvement in flow-mediated endothelium-dependent dilatation (FMD) of the brachial artery and brachial-ankle pulse wave velocity (baPWV) has an additive effect on achieving optimal goals of traditional risk factors to reduce cardiovascular risk in patients with coronary artery disease (CAD). We assessed 323 patients with CAD and impaired vascular function, defined as an impaired FMD of the brachial artery (<5.5%) and increased baPWV (>1,440 cm/sec). After FMD and baPWV measurements at 24 weeks of optimal medical treatment (OMT), the study patients were followed up for <60 months or until a composite of cardiac death, nonfatal myocardial infarction (MI), unstable angina, or ischemic stroke occurs. During the median follow-up period of 35 months, cardiovascular events occurred in 72 patients. Multivariate Cox hazards analysis showed that patients with an improvement in FMD and baPWV had the lowest probability of future cardiovascular events. In addition, the improvement in FMD and baPWV had a significant incremental effect on the predictive value of the achievement of optimal goals for blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), and hemoglobin A1c (HbA1c) using net reclassification improvement (NRI) and integrated discrimination improvement (IDI). The improvement in FMD and baPWV had additive effects on risk reduction of the achievement of the optimal goals of traditional risk factors in patients with CAD. Thus, serial measurements of FMD and baPWV may be useful for identifying CAD patients at residual risk for adverse cardiovascular events following OMT.
Identifiants
pubmed: 33229855
doi: 10.5551/jat.57562
pmc: PMC8592703
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1133-1144Références
N Engl J Med. 2007 Jun 7;356(23):2388-98
pubmed: 17554120
Heart Vessels. 2009 Sep;24(5):340-6
pubmed: 19784816
Cardiology. 2015;131(2):69-79
pubmed: 25872009
J Am Coll Cardiol. 2003 Oct 1;42(7):1149-60
pubmed: 14522472
J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27
pubmed: 20338492
Hypertension. 2018 Nov;72(5):1060-1071
pubmed: 30354826
Int J Cardiol. 2015 Jan 15;178:226-31
pubmed: 25464260
Circ J. 2010 Jan;74(1):24-33
pubmed: 19920359
J Am Coll Cardiol. 2005 Aug 16;46(4):648-55
pubmed: 16098430
Atherosclerosis. 2005 Aug;181(2):321-7
pubmed: 16039286
J Am Coll Cardiol. 2006 May 16;47(10):2130-9
pubmed: 16697342
Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):168-75
pubmed: 12588755
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12
pubmed: 17569110
Atherosclerosis. 2009 Jul;205(1):221-6
pubmed: 19135671
J Am Coll Cardiol. 2009 Jan 27;53(4):323-30
pubmed: 19161880
Cardiovasc Diabetol. 2016 Nov 3;15(1):150
pubmed: 27809848
Eur J Endocrinol. 2008 Oct;159(4):399-406
pubmed: 18653546
Ann Intern Med. 2009 Jun 2;150(11):795-802
pubmed: 19487714
N Engl J Med. 2000 Sep 28;343(13):915-22
pubmed: 11006367
Circulation. 2016 Nov 8;134(19):1419-1429
pubmed: 27682883
Lancet. 2000 Jan 1;355(9197):19-24
pubmed: 10615886
J Cardiol. 2014 Sep;64(3):179-84
pubmed: 24556367
Circ J. 2005 Jul;69(7):815-22
pubmed: 15988107
Circulation. 2003 Jan 7;107(1):149-58
pubmed: 12515758
J Cardiol. 2020 Mar;75(3):270-274
pubmed: 31500961
J Cardiol. 2012 Jul;60(1):12-7
pubmed: 22445441
Int J Cardiol. 2013 Jul 31;167(2):555-60
pubmed: 22326513
Eur Heart J. 2006 Nov;27(21):2588-605
pubmed: 17000623